Bibliography
Found 52 results
Filters: Author is Scott Letendre [Clear All Filters]
HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS. 2016 ;30(17):2591-2597.
Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology [Internet]. 2005 ;64(8):1343-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15851720
. Global NeuroAIDS roundtable. J Neurovirol. 2013 ;19(1):1-9.
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. Journal of Virology [Internet]. 2005 ;79(3):1772-88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15650202
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain: A Journal of Neurology [Internet]. 2006 ;129:1872-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16735456
Frequency and predictors of self-reported prospective memory complaints in individuals infected with HIV. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists [Internet]. 2007 ;22:187-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17289343
. Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.
Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Annals of Neurology [Internet]. 2004 ;56:416-23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15349869
. Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. Journal of Neurovirology [Internet]. 2007 ;13:150-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17505983
. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS (London, England) [Internet]. 2005 ;19 Suppl 3:S72-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16251831
. Editorial commentary: Severe HIV-associated CD8+ T-cell encephalitis: is it the tip of the Iceberg?. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America [Internet]. 2013 ;57:109-11. Available from: https://www.ncbi.nlm.nih.gov/m/pubmed/23515206/?i=1&from=/23515206/related
. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. Journal of Neuroimmunology [Internet]. 2005 ;169(1-2):144-52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16182380
. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.
Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.
A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol. 2013 ;8(5):1123-35.
. Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. Journal of the International Neuropsychological Society: JINS [Internet]. 2003 ;9(1):64-71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12570359
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. Journal of Neurovirology [Internet]. 2009 ;15:360-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20175693
Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathology (Zurich, Switzerland) [Internet]. 2003 ;13(2):195-210. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12744473
. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019 ;33(3):475-481.
CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. Journal of Neuroimmunology [Internet]. 2004 ;157(1-2):185-92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15579296
. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. Journal of NeuroVirology [Internet]. 2005 ;11(4):356-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16206458
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
Alterations in the levels of vesicular trafficking proteins involved in HIV replication in the brains and CSF of patients with HIV-associated neurocognitive disorders. Journal of Neuroimmune Pharmacology [Internet]. 2013 ;8(5):1197-1209. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24292993
.